-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Drug Basics FTP-198 Main Profile FTP-198 Series Hesco developed a class 1 innovative chemical drug intended for the treatment of idiolytic pulmonary fibrosis (IPF).
IPF is a chronic, aggressive fibrosis lung disease with unknown epathy, which can cause peripheral pulmonary fibrosis remodeling, leading to respiratory failure, the incidence of which increases with age, and is common in people aged 60 to 70 years, and is the most common idynogenic interstitity pneumonia.
IBF is diagnosed with a medium survival of 2 to 5 years, the mortality rate is high, is one of the respiratory system's incurable diseases.
, IPF has not been a significantly effective treatment, so there is an urgent need for a new treatment that is effective and more to-bearable.
The target mechanism of this product is clear, there is the potential for expandable adaptive disorders, in addition to fibrosis, it is possible to expand tumors, angiogenesty, autoimmune diseases, inflammation, NASH, neurodegenerative lesions and other adaptive disorders, the company will be based on the situation of the species or will carry out the above-mentioned expansion of adaptive disease research and development.
FTP-198 Clinical Trials FTP-198 passed the Australian Ethics Review in January 2020 and conducted a single/multiple dosing, randomized, double-blind, placebo-controlled, dose incremental study of healthy people in the first quarter of 2020.
